Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Xenon today and set a price target of $80.00. Kasimov covers the Healthcare sector, fo...

Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)

An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals reported its second-quarter 2026 results on August 6, highlighting strong ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$63.36	-1.84%	720.24K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$63.36	-1.8%	720.24K
3
4
5
6

XENE

XENE

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel